This article is more than 5 years old. Information may no longer be current.

FDA should have results from B&L inspections this month

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

According to the Food and Drug Administration, joint inspections between the agency and Bausch & Lomb into the company’s Greenville, S.C., plant should be completed this month. That facility was responsible for the manufacture of ReNu with MoistureLoc, a contact lens solution now at the center of controversy over its possible role in the confirmed cases of Fusarium keratitis reported over the past few months.

As of late April, a total of 73 cases in the United States had been confirmed with fungal keratitis, with another 113 still under investigation, according to FDA. The Centers for Disease Control and Prevention now list 29 states or territories with a confirmed case or one under investigation.

B&L stopped shipping ReNu with MoistureLoc last month, and urged retailers to pull the solution from its shelves.

Government officials in Hong Kong said B&L had been alerted of microbial keratitis outbreaks as early as September of last year, according to a report from Reuters. The Hong Kong Health Department tested samples of B&L’s ReNu with MoistureLoc but “found nothing,” according to Reuters.